AstraZeneca caps out-of-pocket costs for inhalers at $35/month for asthma/COPD patients, effective June 1.
AstraZeneca is capping out-of-pocket costs for inhalers and related medication at no more than $35 per month, effective June 1. This move targets vulnerable patients with asthma or chronic obstructive pulmonary disease, particularly those without health insurance. AstraZeneca's expanded savings programs aim to address barriers to access and affordability for patients with respiratory diseases.
March 18, 2024
20 Articles